Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

ginning at 8 P.M. EDT. Access numbers for this replay are 888-203-1112 (U.S./Canada) and 719-457-0820 (international); participant code 4106309.

Amicus' press releases are available at http://www.amicustherapeutics.com

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera for the treatment of Gaucher disease. The Company recently completed Phase I clinical trials of AT2220 for the treatment of Pompe disease.

Forward-Looking Statements

This Press release contains and the accompanying conference call will contain "forward-looking statements" within the meaning of Section 21E of the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should" and "could," and similar expressions or words identify forward-looking statements. Examples of such statements include: (i) statements regarding the goals and expected timing of clinical studies, including the effect of the completion of the Phase 2 clinical trial for Amigal for the treatment of Fabry disease, the timing and design of Phase 3 clinical development for Amigal, the Phase 2 clinical trials for Plicera for the treatment of Gaucher disease, the effect of
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2014)... 2014 The Global and China ... in-depth study on the current state of the ... , The report provides a basic overview of ... structure. Global market analysis and Chinese domestic market ... developments, trends and competitive landscape of the market. ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Pittcon is ... MacDonald, and colleague Koichiro Matsuda, Horiba Scientific, have organized ... September 5, 2014. JASIS , Asia’s largest analytical ... 2014, in Makuhari Messe, Japan. , The four ... for Bioanalysis from Single Molecules to Single Cells” will ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 A major ... the biotech start-up dense realm of Boston-Cambridge, is gaining ... able investors. James Sherley, the Director of Boston’s Adult ... the local and national visibility of his company an ... 2013. , In addition to a social media marketing ...
(Date:8/28/2014)... Lawrence, MA (PRWEB) August 28, 2014 “This ... single test to screen from 0 to 150 ppb,” said ... test is a significant benefit to plant owners and USDA-GIPSA ... corn and other commodities. Testing can take place in a ... Not only can the plant test the feed and grain ...
Breaking Biology Technology:Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 2Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 3Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4
... nation combats an,alarming rise in chronic diseases, the ... a new report on the next,generation of medicines ... patients., The report found that America,s pharmaceutical ... Michigan - are,testing a record 633 new biotech ...
... ... Bioprocess Industry, ELKTON, Md., ... -- an online interactive design tool that,provides step-by-step instructions for ... STA-PURE(SM) Bioprocess Configurator is unique to the,bioprocess industry. Available at ...
... on Track, SAN MATEO, Calif., Sept. 24 ... company focused on developing and,commercializing novel pain management ... to the European Medicines Agency,s (EMEA) Day 120,questions ... in peripheral neuropathic pain., NeurogesX, MAA for ...
Cached Biology Technology:New Report on 633 Biotechnology Medicines Under Development Released in Michigan 2New Report on 633 Biotechnology Medicines Under Development Released in Michigan 3Gore's Legacy of Innovation Extends From Products to Processes 2Gore's Legacy of Innovation Extends From Products to Processes 3NeurogesX Responds to EMEA's Day 120 Questions 2NeurogesX Responds to EMEA's Day 120 Questions 3
(Date:8/29/2014)... Some species of marine phytoplankton, such as the prolific ... vitamin B1 (thiamine), researchers have discovered. The finding contradicts ... many other eukaryotic microbes depend on scarce supplies of ... really different way to think about the ocean," says ... The ISME Journal paper with CIFAR fellows ...
(Date:8/29/2014)... of the Tibetan plateau -- the largest topographic anomaly ... both its profound effect on climate and its reflection ... GSA Bulletin , Katharine Huntington and colleagues employ a ... modern and fossil snail shells to investigate the uplift ... , Views range widely on the timing of surface ...
(Date:8/28/2014)... have identified a handful of bacterial culprits that may ... and ulcerative colitis, using patients, own intestinal immune responses ... 28 in the journal Cell . , Trillions ... plays a critical role in the development and progression ... number of bacterial species affect a person,s susceptibility to ...
Breaking Biology News(10 mins):Not all phytoplankton in the ocean need to take their vitamins 2Not all phytoplankton in the ocean need to take their vitamins 3Snails tell of the rise and fall of the Tibetan Plateau 2Snails tell of the rise and fall of the Tibetan Plateau 3Snails tell of the rise and fall of the Tibetan Plateau 4Snails tell of the rise and fall of the Tibetan Plateau 5Snails tell of the rise and fall of the Tibetan Plateau 6Snails tell of the rise and fall of the Tibetan Plateau 7Yale study identifies possible bacterial drivers of IBD 2
... coral bleaching prediction system indicates that there will be ... the event will probably not be severe. NOAA issued ... the 11th International Coral Reef Symposium in Ft. Lauderdale, ... a risk of widespread bleaching in the Northwestern Hawaiian ...
... Mass., July 10, 2008 -- The National Institutes of ... to Williams College Assistant Professor of Biology Lara D. ... or CMT. CMT is the most common inherited ... 2,500 individuals. CMT usually shows dominant inheritance and symptoms ...
... a million electrical signals pulsing through your body. At the ... the ion channel. A new study by researchers from ... a meter in ion channels. This movement is critical to ... close in response to changes in voltage across the membrane. ...
Cached Biology News:New NOAA coral bleaching prediction system calls for low level of bleaching in Caribbean this year 2Researchers catch ion channels in their opening act 2Researchers catch ion channels in their opening act 3
Human RXR beta/NR2B2 MAb (Clone H7341) Keywords: RXRbeta, RXRbeta, Retinoid X Receptor beta...
PSMD1 Antibody...
Terrific Broth, 1 kg. Mixture of casein peptone, yeast extract, K2HPO4, and KH2PO4.Used at 47 g/l for E. coli growth with higher cell densities. Category: Nucleotides & Enzymes & Biochemicals, Ultrap...
... 1200L sets the new standard for ... incorporating the latest technologies and providing ... analytical needs. The Atmospheric Pressure ... Quadrupole Analyzer provide superior selectivity and ...
Biology Products: